Mebeverine Teva

Mebeverine, the active ingredient in Mebeverine Teva, is an antispasmodic presented as an oral tablet for oral use. It is employed to relieve abdominal cramps and discomfort associated with irritable bowel syndrome and other functional gastrointestinal disorders in adult patients. It works by relaxing smooth muscle in the gastrointestinal tract, helping to normalize bowel movements.

GNH USA supplies Mebeverine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Mebeverine is used to treat functional gastrointestinal conditions by reducing smooth‑muscle spasms.

Irritable bowel syndrome: alleviates abdominal pain, cramping and irregular bowel habits associated with the condition. Functional gastrointestinal disorders: reduces spasmodic episodes and improves patient comfort. Spastic colon: diminishes colonic muscle contractions, helping to normalize transit.

Mebeverine may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth - Nausea - Headache - Dizziness - Abdominal discomfort - Constipation

Serious or Rare Side Effects: - Allergic reactions (rash, itching, swelling) - Severe skin eruptions such as Stevens‑Johnson syndrome - Angioedema - Cardiac arrhythmia (rare) - Hepatic dysfunction (very rare)

Before initiating therapy, consider the following safety measures.

Assess renal and hepatic function: adjust use if significant impairment is present. Monitor for allergic reactions: discontinue if rash, swelling or breathing difficulty occurs. Avoid use in patients with known hypersensitivity to mebeverine or excipients. Inform patients about possible dizziness: advise caution when driving or operating machinery. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Mebeverine may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Strong anticholinergic agents: may increase antispasmodic effect and risk of constipation. - Monoamine oxidase inhibitors (MAOIs): potential for exaggerated gastrointestinal effects.

Moderate Interactions (Monitor Closely): - Other antispasmodic drugs: additive smooth‑muscle relaxation. - CYP450 substrates: mebeverine may alter metabolism of certain drugs. - Antidepressants (e.g., tricyclics): monitor for increased gastrointestinal side effects.